T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01946373|
Recruitment Status : Recruiting
First Posted : September 19, 2013
Last Update Posted : October 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Melanoma||Drug: Cyclophosphamide Drug: Fludarabine Biological: T cells Biological: Interleukin-2 Biological: Dendritic cell vaccine||Phase 1|
The MAT02 clinical trial is a phase 1 clinical trial with the objective to assess the safety, feasibility and immunological efficacy of the combined application of two immunological treatment modalities in patients with metastatic melanoma:
- Cohort A: After a non-myeloablative conditioning regimen, 5 patients will receive one bulk infusion of T cells. T cells will be expanded ex vivo from autologous tumor infiltrating lymphocytes (TIL). In vivo persistence of the infused cells will be supported by administration of IL-2, a T cell survival factor.
- Cohort B: This adoptive cell transfer (ACT) step will in additional 10 patients be followed by a vaccination with autologous, in vitro-generated, dendritic cells (DC), loaded with autologous tumor lysate and a synthetically produced peptide derived from the tumor associated antigen NY-ESO 1.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma|
|Actual Study Start Date :||October 2013|
|Estimated Primary Completion Date :||December 2025|
|Estimated Study Completion Date :||December 2025|
Experimental: Chemotherapy + T cells + IL-2
Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
Biological: T cells
Experimental: Chemotherapy + T cells + IL-2 + DCV
Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
Biological: T cells
Biological: Dendritic cell vaccine
- Safety of the T cell therapy, with and without dendritic cell vaccine, as evaluated according to the NCI CTCAE scale version 4.0 [ Time Frame: 30 days ]
- Time to disease progression assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. [ Time Frame: 4 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 74 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients with measurable (direct on body surface or by x-ray and/or CT) malignant melanoma (including uveal melanoma), that is advanced, inoperable stage III (advanced regional lymph node metastases, or more than 5 in-transit metastases, N2) or stage IV (distant metastasis, M1) according to the AJCC classification and confirmed by histology/cytology and appropriate radiological investigations.
- Patients with a palpable resectable lesion located in the skin or in a lymph node or a lesion accessible by (core) biopsy.
- Disease should be in progression and the patient should have exhausted other approved therapeutic options, if not the physician considers that an earlier study entry benefits the patient.
- Ambulatory performance status (ECOG 0, 1, 2).
- Age 18-74 and life expectancy greater than 3 months.
- Any of the above criteria are not met.
- Significant history or current evidence of cardiovascular disease (e.g. uncontrolled congestive heart failure or hypertension, unstable coronary artery disease or serious arrhythmias) or major respiratory diseases. In questionable cases, a stress test should be performed.
- Recipients of a major organ allograft. Autoimmune diseases such as, but not limited to, inflammatory bowel disease or multiple sclerosis. Vitiligo is not an exclusion criterion. Other serious chronic diseases.
- Other serious illnesses, e.g. active infections requiring antibiotics, bleeding disorders.
- Has had prior systemic cancer therapy within the past four weeks at the time of the start of the lymphodepletion regimen.
- Patients diagnosed with prior malignancies (except adequately treated basal cell carcinomas of the skin or in situ carcinomas of the skin or in situ carcinomas of the cervix, surgically cured) within the past 5 years.
- Patients with second advanced malignancies concurrently.
- Active CNS metastases. (Note: Patients with brain metastases that have been completely resected at least one month prior to registration or have undergone gamma knife treatment with no evidence of recurrence on CT and who are neurologically stable, are not excluded).
- Organic brain syndrome or significant psychiatric disorder which would preclude participation in the full protocol and follow-up.
- Immunodeficiency, previous splenectomy or radiation therapy of the spleen.
Screening laboratory values:
a) Inadequate hematologic function defined by: i) White blood count (WBC) <3.0 x 109/l ii) Platelet count <100x109/l iii) Hemoglobin level <100 g/l b) Inadequate hepatic function as defined by either: i) Total bilirubin level >1.5 times the upper limit of normal (ULN) ii) Aspartate amino transferase (AST) or alanine amino transferase (ALT) >3 times the ULN (if related to liver metastases >5 times the ULN) c) Inadequate renal function defined as serum creatinine >1.5 times the ULN
- Infectious diseases that can be transmitted via contact with blood, such as HIV, Hepatitis B and C.
- Women who are pregnant or nursing will be excluded because of the potentially dangerous effects of the preparative chemotherapy on the fetus.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01946373
|Contact: Maria Wolodarski, MDemail@example.com|
|Contact: Rolf Kiessling, MD, PhDfirstname.lastname@example.org|
|Karolinska University Hospital||Recruiting|
|Stockholm, Sweden, SE-171 76|
|Contact: Maria Wolodarski, MD +46851770000 email@example.com|
|Principal Investigator: Maria Wolodarski, MD|
|Principal Investigator:||Maria Wolodarski, MD||Karolinska University Hospital|
|Responsible Party:||Maria Wolodarski, Dr, Karolinska University Hospital|
|Other Study ID Numbers:||
2012-000450-63 ( EudraCT Number )
|First Posted:||September 19, 2013 Key Record Dates|
|Last Update Posted:||October 4, 2022|
|Last Verified:||October 2022|
Dendritic cell vaccination
Adoptive cell transfer
Tumor infiltrating lymphocytes
Phase I study
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Physiological Effects of Drugs
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Sensory System Agents
Peripheral Nervous System Agents